Reference number(s)
1637-H

SPECIALTY QUANTITY LIMIT PROGRAM

EMFLAZA (deflazacort)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of Duchenne muscular dystrophy fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

II. COVERED QUANTITIES

Medication	Standard Limit	FDA-Recommended Dosing
Emflaza tablets 6 mg	60 tablets per 30 days	0.9 mg/kg/day*
Emflaza tablets 18 mg	30 tablets per 30 days	
Emflaza tablets 30 mg	30 tablets per 30 days	
Emflaza tablets 36 mg	30 tablets per 30 days	
Emflaza suspension: 22.75 mg/mL	52 mL per 30 days (1.8 mL/day)	

* The maximum dose of deflazacort recommended by clinical practice guidelines is 36 to 39 mg per day.

III. REFERENCES

1. Emflaza [package insert]. Northbrook, IL: Marathon Pharmaceuticals, LLC; June 2017.
2. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis and pharmacological and psychosocial management. *Lancet Neurol*. 2010;9:77-93.

CVS caremark™